<Version>
  <xmlSource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlSource>
  <Section SecID="390" OrdBy="100" Name="General">
    <Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Management of a suspicious adnexal mass.&lt;/div&gt;" />
    </Field>
    <Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dodge J, Covens A, Lacchetti C, Elit L, Le T, Devries-Aboud M, Fung Kee Fung M, Gynecology Cancer Disease Site Group. Management of a suspicious adnexal mass. Toronto (ON): Cancer Care Ontario (CCO); 2011 Jul 7. Various p.&amp;nbsp;(Evidence-based series; no. 4-15).&amp;nbsp; [294 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Cancer Care Ontario Program in Evidence-Based Care (CCO PEBC) reaffirmed the currency of this guideline in October 2016. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Please visit the &lt;a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=100599&quot; title=&quot;CCO Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt; for details on any new evidence that has emerged and implications to the guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="420" OrdBy="300" Name="Recommendations">
    <Field FieldID="151" OrdBy="310" ID="421" Name="Major Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Identification of an Adnexal Mass Suspicious for Ovarian Cancer&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sonography, particularly three-dimensional (3D) sonography, magnetic resonance imaging (MRI), and computerized tomography (CT) imaging, are each recommended for differentiating malignant from benign ovarian masses. However, the working group offers the following further recommendations, based on their expert consensus opinion and the consideration of availability, access, and harm:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Transvaginal sonography should be the first modality of choice, where technically feasible, in patients with a suspicious, isolated ovarian mass. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;MRI is the most appropriate test to help clarify the malignant potential in patients where ultrasound may be unreliable. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;CT is most useful in cases where extra ovarian disease is suspected or needs to be ruled out. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of an adnexal mass by Doppler technology alone is not recommended. Doppler technology should be combined with a morphological assessment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ultrasound-based morphological scoring systems can be used to differentiate benign from malignant adnexal masses. These systems are based on specific ultrasound parameters, each with several scores according to determined features. All evaluated scoring systems were found to have an acceptable level of sensitivity and specificity; therefore, the choice of scoring system may be made based on clinician preference. More information on the characteristics of these scoring systems can be found in Appendix 1 in the original guideline document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;As a stand-alone modality, serum CA-125 is not recommended for distinguishing between benign and malignant adnexal masses. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frozen section for the intraoperative diagnosis of a suspicious adnexal mass is recommended in settings where availability and patient preferences allow. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Surgical Procedures for an Adnexal Mass Suspicious for Malignancy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comprehensive surgical staging with lymphadenectomy is recommended for the surgical management of patients with early-stage ovarian cancer to improve survival. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laparoscopy is a reasonable alternative to laparotomy, provided appropriate surgery and/or staging can be done. The choice between laparoscopy and laparotomy should be based on patient and clinician preferences. Discussion with a gynecologic oncologist is recommended. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fertility-preserving surgery is an acceptable alternative to more extensive surgery in patients with low-malignant potential (LMP) tumours and those with well-differentiated surgically staged 1 ovarian cancer. Discussion with a gynecologic oncologist is recommended. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="138" OrdBy="330" ID="423" Name="Clinical Algorithm(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="396" OrdBy="400" Name="Scope">
    <Field FieldID="140" OrdBy="405" ID="397" Name="Disease/Condition(s)" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Suspicious adnexal mass, either symptomatic or asymptomatic&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="103" OrdBy="410" ID="398" Name="Guideline Category" Type="picklist-many">
      <FieldValue Value="Assessment of Therapeutic Effectiveness" />
      <FieldValue Value="Evaluation" />
      <FieldValue Value="Management" />
      <FieldValue Value="Treatment" />
    </Field>
    <Field FieldID="113" OrdBy="415" ID="399" Name="Clinical Specialty" Type="picklist-many">
      <FieldValue Value="Obstetrics and Gynecology" />
      <FieldValue Value="Oncology" />
      <FieldValue Value="Pathology" />
      <FieldValue Value="Radiology" />
      <FieldValue Value="Surgery" />
    </Field>
    <Field FieldID="114" OrdBy="420" ID="400" Name="Intended Users" Type="picklist-many">
      <FieldValue Value="Physicians" />
    </Field>
    <Field FieldID="129" OrdBy="425" ID="401" Name="Guideline Objective(s)" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To evaluate the optimal strategy for preoperative identification of the adnexal mass suspicious for ovarian cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To evaluate the most appropriate surgical procedure for a woman who presents with an adnexal mass suspicious for malignancy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
    <Field FieldID="132" OrdBy="430" ID="402" Name="Target Population" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adult women presenting with a suspicious adnexal mass, either symptomatic or asymptomatic&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="133" OrdBy="435" ID="403" Name="Interventions and Practices Considered" Type="text">
      <FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Identification of an adnexal mass suspicious for ovarian cancer&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Sonography (three-dimensional sonography, transvaginal sonography) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Magnetic resonance imaging (MRI) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Computerized tomography (CT) imaging &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Doppler technology combined with morphological assessment &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of ultrasound-based morphological scoring systems &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Serum CA-125 (not recommended as stand-alone modality) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Frozen section for the intraoperative diagnosis of a suspicious adnexal mass &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical procedures for an adnexal mass suspicious for malignancy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Comprehensive surgical staging with lymphadenectomy in patients with early-stage ovarian cancer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Laparoscopy as a reasonable alternative to laparotomy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Fertility-preserving surgery as an acceptable alternative to more extensive surgery &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" />
    </Field>
    <Field FieldID="134" OrdBy="440" ID="404" Name="Major Outcomes Considered" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Optimal surgery &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Overall survival &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Disease-free survival &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progression-free survival &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction in the number of surgeries &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Morbidity &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="405" OrdBy="500" Name="Methodology">
    <Field FieldID="109" OrdBy="505" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many">
      <FieldValue Value="Hand-searches of Published Literature (Primary Sources)" />
      <FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" />
      <FieldValue Value="Searches of Electronic Databases" />
    </Field>
    <Field FieldID="135" OrdBy="510" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Original Guideline&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Literature Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Environmental Scan&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As a first step, an internet search of Canadian and international health organizations and the National Guideline Clearinghouse (see Appendix 1 in the original guideline document for full list) was conducted for existing guidelines and systematic reviews relevant to the research question. Guidelines were included if they were published since 1999 in English. This initial environmental scan yielded 11 practice guidelines; however, one guideline was excluded because the full guideline was available only in French, and another guideline was excluded because only the National Guideline Clearinghouse summary was available. One evidence report/technology assessment and one clinical practice guideline identified through this environmental scan were deemed to be the most appropriate to answer the guideline questions. The 2006 Agency for Healthcare Research and Quality (AHRQ) report addressed the identification of an adnexal mass suspicious for malignancy question. The 2004 Australian Cancer Network (ACN) Clinical Practice Guideline addressed the surgical management of an adnexal mass suspicious for malignancy question.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Update Literature Search Strategy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The literature search from the AHRQ report was updated (see Appendix 2 in the original guideline document) using MEDLINE (OVID: January 2004 through week 3, March 2009). In addition, as an exact search strategy for the Australian Cancer Network report was not available, an update of that literature search (see Appendix 2 in the original guideline document) was approximated using the keywords provided in the report using MEDLINE (OVID: January 2004 through week 3, April 2009). This literature search combined disease-specific terms ('pelvic mass,' 'adnexal mass,' 'pelvic neoplasms,' 'ovarian cancer,' 'ovarian neoplasm,' 'ovarian carcinoma,' 'epithelial ovarian cancer,' 'borderline ovarian tumours' and 'tumours of low malignant potential') with surgical specific terms ('intraoperative pathological examination,' 'frozen section,' 'debulking surgery,' 'fertility sparing,' 'surgical staging,' 'bilateral salpingo-oophorectomy,' 'total hysterectomy,' 'node or nodal dissection,' 'surgical management,' 'treatment,' 'cytoreduction,' 'secondary cytoreduction,' 'interval cytoreduction,' 'laparotomy,' and 'laparoscopy') for all study designs.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Relevant articles and abstracts were selected and reviewed by two reviewers. The reference lists of included studies along with the personal reference lists of the guideline working group were searched for additional studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Study Selection Criteria&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Articles were eligible for inclusion in this systematic review if they were systematic reviews, meta-analyses, clinical practice guidelines, randomized trials, or comparative cohort studies. Studies identified in the update of the AHRQ report literature search were included based on the same inclusion criteria put forth in the AHRQ report.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For studies investigating single modality identification of an adnexal mass, the inclusion criteria were:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Comparison of the test (e.g., bimanual pelvic exam or ultrasound, to histology or negative surgery) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Greater than 20 patients included in study &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Able to construct a 2-by-2 table, which compares the results of the diagnostic test with the definitive histological diagnosis &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;For studies investigating the use of multi-modality scoring systems (i.e., Risk of Malignancy Index [RMI]), the inclusion criteria were:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with suspicion of cancer &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Studies with scoring, risk score, combined modality approach &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Assesses predictive value of two or more variables using multivariable model &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Greater than 50 patients included in study &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;Studies identified in the update of the Australian Cancer Network guideline were based on the following selection criteria:&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Greater than 20 patients included in study &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with an adnexal mass suspicious for early stage (I-II) malignancy, &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Two-armed (or greater) study design with a comparison of surgical procedures/techniques/approaches &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Report on at least one of the following outcomes: optimal surgery, overall survival, progression-free or disease-free survival, reduction in the number of surgeries, morbidity, adverse events, quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;2016 Reaffirmation&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A comprehensive search of published medical literature was conducted from 2009 to July 2016 using Medline, EMBASE and Cochrane databases. Abstracts of conferences were not searched separately, but were picked up from the EMBASE search. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Literature Search Strategy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Terms describing performance of tests and prediction models in identifying adnexal mass suspicious for malignancy and surgical management of adnexal mass suspicious for malignancy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Pelvic Exam Performance&lt;/em&gt;: Pelvic exam.mp. (bimanual adj pelvic) .mp. (physical exam and pelvis) .mp. (diagnostic techniques, obstetrical and gynecological&quot;/ culdoscopy/ laparoscopy/ physical examination/ Physical examination/ Ovarian cysts/ ovarian neoplasms/ genital neoplasms, Female/ or adnexal diseases/ adnexal mass.mp. Exp ovarian cysts/ exp ovarian neoplasms/ genital neoplasms, female/ adnexal diseases/ adnexal mass.mp. Exp fallopian tube diseases/ &quot;diagnostic techniques, obstetrical and gynecological&quot;/ Culdoscopy/&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Test Performance&lt;/em&gt;: (vagin$ adj ultraso$).mp. (adnex$ adj2 mas$).mp. (pelvi$ adj mas$).mp. (ovar$ adj mas$) .mp. &quot;sensitivity and specificity&quot;/ (ovar$ adj tumo$) .mp. ROC curve/&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Predictive Models&lt;/em&gt;: (vagin$ adj ultraso$).mp. (adnex$ adj2 mas$).mp. (pelvi$ adj mas$).mp. (ovar$ adj mas$).mp. &quot;sensitivity and specificity&quot;/ Predictive value of tests/ Risk assessment/ ROC curve/ &quot;multivariate analysis&quot; / &lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Surgical Management&lt;/em&gt;: Pelvic mass.tw,ti. Adnexal mass.tw,ti. Exp pelvic neoplasms/ (ovary and (cancer or carcinoma or neoplasm?)).tw,ti. (ovarian and (cancer or carcinoma or neoplasm?)).tw,ti. Exp ovarian neoplasms/ Borderline ovarian tumo?r$.tw,ti. Tumo?r$ of low malignant potential.tw,ti. lntraoperative pathological examination$.tw,ti. Exp frozen section/ Frozen section$.tw,ti. Debulking surgery.tw,ti. Exp surgical procedures, operative/ Cytoreduction$ .tw,ti. Fertility conservation,tw,ti. Fertility sparing.tw,ti. Surgical management.tw,ti. Secondary cytoreduction.tw,ti. Interval cytoreduction .tw,ti. Surgical staging.tw,ti. BSO.tw,ti. Bilateral salpingo-oophorectomy.tw,ti. Bilateral salpingo oophorectomy.tw,ti. Surgical stage.tw,ti. Total hysterectomy.tw,ti. Hysterectomy.tw,ti. ((node or nodal) and dissection) .tw,ti. Exp laparotomy/ Exp laparoscopy/ &lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Inclusion Criteria: systematic reviews, meta-analyses, clinical practice guidelines, randomized trials, or comparative cohort studies that investigated single modality identification of an adnexal mass, or investigated the use of multi-modality scoring systems, or were a two-armed (or greater) study design with a comparison of surgical procedures, techniques or approaches &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="136" OrdBy="515" ID="408" Name="Number of Source Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Original Guideline&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Identification of an Adnexal Mass Literature&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Four meta-analyses and 67 primary studies, pertaining to the identification of an adnexal mass suspicious for malignancy, met the inclusion criteria and are included in this review.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Surgical Procedures Literature&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A total of 1809 articles were identified in the updated search for the most appropriate surgical procedure, of which 16 met the inclusion criteria.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;2016 Reaffirmation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Four separate searches were completed which yielded a total of 10,412 hits. Four hundred and one were retained for full text review. After the full text review, 104 studies were retained to be abstracted.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="115" OrdBy="520" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice">
      <FieldValue Value="Expert Consensus (Committee)" />
    </Field>
    <Field FieldID="149" OrdBy="525" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="116" OrdBy="530" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many">
      <FieldValue Value="Meta-Analysis of Randomized Controlled Trials" />
      <FieldValue Value="Review of Published Meta-Analyses" />
      <FieldValue Value="Systematic Review with Evidence Tables" />
    </Field>
    <Field FieldID="150" OrdBy="535" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Original Guideline&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Synthesizing the Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A bivariate, random-effects meta-regression model was used to produce summary estimates of sensitivity and specificity and to plot summary receiver operating characteristic (ROC) curves with 95% confidence regions. This model, described in detail elsewhere, has several advantages over the standard summary ROC approach. Chief among these is the preservation of the two-dimensional nature of the data and the incorporation of any correlation that might exist between sensitivity and specificity. The model assumes that the logit sensitivities and specificities are normally distributed and makes use of the variance estimates to compute study weights. Heterogeneity in the current review was assessed visually. Given that between-study heterogeneity is widespread for measures of diagnostic accuracy, a random-effects model was used for all pooling. This bivariate, random-effects model takes into account the difference in precision by which sensitivity and specificity have been measured within and across studies, and it incorporates and estimates the amount of between-study variability. Statistical analyses were executed with the statistical software package STATA version 11 using the metandi command. The outcomes of the meta-analyses were plotted as summary ROC curves and can be seen in Figures 2A-D in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Gynecology Cancer Disease Site Group (DSG) decided not to pool the surgical studies, but rather to present the results of each study individually in a descriptive fashion.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Quality Appraisal and Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Appraisal of Guidelines Research and Evaluation (AGREE) tool was used to evaluate the quality of identified evidence-based guidelines. While all scoring domains of the AGREE tool were considered in the evaluation of guidelines, the Rigour of Development domain, describing the rigour of systematic methods in identifying and evaluating evidence, was considered to be most relevant in application for this systematic review. Systematic reviews and meta-analyses were assessed for quality using the AMSTAR tool. The quality of primary studies included ass&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The guideline document was assessed in accordance with the PEBC Document Assessment and Review Protocol and was determined to require a review. As part of the review, a PEBC methodologist conducted an updated search of the literature. A clinical expert reviewed and interpreted the new eligible evidence. The clinical expert determined that the new evidence supported the existing recommendations and the Gynecology Cancer DSG agreed that the recommendations should be endorsed*. For more information, see the &lt;em&gt;Management of a Suspicious Adnexal Mass: Document Assessment and Review&lt;/em&gt; (see the &quot;Availability of Companion Documents&quot; field). &lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;*&lt;em&gt;Endorsed&lt;/em&gt;: An endorsed document is a document that the DSG/GDG has reviewed for currency and relevance and determined to be still useful as guidance for clinical decision making. A document may be endorsed because the DSG/GDG feels the current recommendations and evidence are sufficient, or it may be endorsed after a literature search uncovers no evidence that would alter the recommendations in any important way.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="112" OrdBy="540" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice">
      <FieldValue Value="Expert Consensus" />
    </Field>
    <Field FieldID="145" OrdBy="545" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Evidence-Based Series (EBS) guidelines developed by the Cancer Care Ontario Program in Evidence-Based Care (CCO PEBC) use the methods of the Practice Guidelines Development Cycle. For this project, the core methodology used to develop the evidentiary base was an update of two previously published systematic reviews: the Agency for Healthcare Research and Quality (AHRQ) report, 2006, and Australian Cancer Network (ACN) Clinical Practice Guideline, 2004. Evidence was selected and reviewed by five members of the PEBC Gynecology Cancer Disease Site Group (DSG) and one methodologist.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The systematic review is a convenient and up-to-date source of the best available evidence on the management of an adnexal mass suspicious for malignancy. The body of evidence in this review is primarily comprised of prospective and retrospective cohort studies. That evidence forms the basis of the recommendations developed by the Gynecology Cancer DSG and published in Section 1 of the original guideline document. The systematic review and companion recommendations are intended to promote evidence-based practice in Ontario, Canada.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="146" OrdBy="550" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="148" OrdBy="565" ID="417" Name="Cost Analysis" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="104" OrdBy="570" ID="418" Name="Method of Guideline Validation" Type="picklist-choice">
      <FieldValue Value="External Peer Review" />
      <FieldValue Value="Internal Peer Review" />
    </Field>
    <Field FieldID="130" OrdBy="575" ID="419" Name="Description of Method of Guideline Validation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Report Approval Panel&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prior to the submission of this Evidence-Based Series (EBS) draft report for external review, the report was reviewed and approved by the Program in Evidence-Based Care (PEBC) Report Approval Panel, which consists of two members, including an oncologist, with expertise in clinical and methodology issues.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;External Review by Ontario Clinicians and Other Experts&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The PEBC external review process is two-pronged and includes a targeted peer review that is intended to obtain direct feedback on the draft report from a small number of specified content experts and a professional consultation that is intended to facilitate dissemination of the final guidance report to Ontario practitioners.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following the review and discussion of Section 1: Recommendations and Section 2: Evidentiary Base of this EBS and the review and approval of the report by the PEBC Report Approval Panel, the Gynecology Cancer Disease Site Group (DSG) circulated Sections 1 and 2 to external review participants for review and feedback.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Methods&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Targeted Peer Review&lt;/em&gt;: During the guideline development process, two targeted peer reviewers from Ontario and one from the United States of America (USA) considered to be clinical and/or methodological experts on the topic were identified by the working group. Several weeks prior to completion of the draft report, the nominees were contacted by email and asked to serve as reviewers. Three reviewers agreed, and the draft report and a questionnaire were sent via email for their review. The questionnaire consisted of items evaluating the methods, results, and interpretive summary used to inform the draft recommendations and whether the draft recommendations should be approved as a guideline. Written comments were invited. The questionnaire and draft document were sent out on April 8, 2011. Follow-up reminders were sent at two weeks (email) and at four weeks (telephone call).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Professional Consultation&lt;/em&gt;: Feedback was obtained through a brief online survey of health care professionals who are the intended users of the guideline. Gynecologists and gynecologic oncologists in the PEBC database were contacted by email to inform them of the survey. Participants were asked to rate the overall quality of the guideline (Section 1 in the original guideline document) and whether they would use and/or recommend it. Written comments were invited. Participants were contacted by email and directed to the survey website where they were provided with access to the survey, the guideline recommendations (Section 1 in the original guideline document) and the evidentiary base (Section 2 in the original guideline document). The notification email was sent on April 13, 2011. The consultation period ended on June 10, 2011. The working group reviewed the results of the survey.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Conclusion&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This EBS report reflects the integration of feedback obtained through the external review process with final approval given by the Gynecology Cancer Disease Site Group, and the Report Approval Panel of the PEBC.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations">
    <Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations are supported by meta-analyses, comparative cohort studies (prospective and retrospective), and randomized controlled trials.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations">
    <Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Identification of an Adnexal Mass Suspicious for Ovarian Cancer&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of six cohort studies that investigated three-dimensional (3D) sonography indicated an enhanced sensitivity of 93.5% and specificity of 91.5% with 3D technology. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of 22 cohort studies with 24 data sets that investigated the effectiveness of magnetic resonance imaging (MRI) in the diagnosis of adnexal masses found an overall sensitivity of 91.9% and specificity of 88.4%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of seven studies with eight data sets considering computed tomography (CT) technology yielded an overall sensitivity of 87.2% and specificity of 84.0%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of the resistance index (RI) included 35 cohort studies with 42 data sets and yielded an overall sensitivity of 77.2% and specificity of 89.8%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of 21 cohort studies with 22 data sets that evaluated the pulsatility index (PI) found an overall sensitivity of 80.6% and specificity of 79.9%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A meta-analysis of the peak systolic velocity (PSV) included seven cohort studies and found an overall sensitivity of 80.0% and specificity of 84.2%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Direct comparisons between ultrasound-based morphological scoring systems were not performed in this review. Instead, the assessment was based on summary data on sensitivity and specificity obtained from the meta-analyses conducted. The meta-analyses found summary sensitivities ranging from 83.5% to 91% and specificities ranging from 63% to 85.9%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Risk of Malignancy Index (RMI) is a clinical prediction rule that includes CA-125 and menopausal status, in addition to ultrasound-based morphology. In a meta-analysis of data from the 13 RMI studies, with 15 data sets, employing a cutoff of 200 to be indicative of malignancy, the summary sensitivity and specificity were 79.2% and 91.7%, respectively. RMI2 and RMI3 are newer versions of this tool, with comparable levels of sensitivity and specificity. The choice of version of RMI should be based on clinician preference. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The recommendation against using serum CA-125 as a stand-alone modality, is based on a meta-analysis of 49 cohort studies and two case-control studies with a total of 52 data sets that found, at a threshold of 35 U/mL, an overall sensitivity of 78.7% and specificity of 77.9%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The recommendation for the use of frozen sections for the intraoperative diagnosis of a suspicious adnexal mass is based on a meta-analysis of frozen section diagnoses that included 15 cohort studies and yielded an overall sensitivity of 89.2% and specificity of 97.9%. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Surgical Procedures for an Adnexal Mass Suspicious for Malignancy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Two large population-based studies found that surgical staging with lymphadenectomy was associated with improved three-year (p&amp;lt;0.001) and five-year disease specific survival (p&amp;lt;0.001) compared to staging procedures without lymphadenectomy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One study reported a statistically significant improvement in five-year overall survival rates in patients undergoing a lymphadenectomy versus those that did not (87% vs. 64%, respectively; p=0.02). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Survival analyses also demonstrated a statistically significant benefit in disease-free survival (p=0.004 and p=0.0007, respectively) for patients undergoing a lymphadenectomy versus those that did not. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In another study that considered overall survival, researchers reported a statistically significant difference (p=0.0008) in the two patient groups in favour of the patients undergoing a lymphadenectomy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One randomized controlled trial (RCT) was identified and reported no statistically significant effect of lymphadenectomy on progression-free (hazard ratio [HR]= 0.72; 95% confidence interval [CI], 0.46 to 1.14) or overall (HR=0.85; 95% CI, 0.49 to 1.47) survival. However, this study was underpowered to detect a difference in survival, the study's secondary outcome. Rather, the sample-size calculation for this RCT was undertaken to detect a difference in prevalence of lymph node positivity. It was deemed inadequate to inform the recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the three studies that considered patients with early epithelial ovarian cancer, no statistical difference in survival rates was detected between patients undergoing a laparoscopy versus laparotomy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the management of patients with early borderline ovarian tumours, two studies found that a laparoscopic versus laparotomic surgical approach did not appear to influence survival rates. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One cohort study specifically compared rates of recurrence in 40 patients who underwent unilateral salpingo-oophorectomy versus 22 patients who underwent cystectomy only. No statistical difference in recurrence rates was detected (27.5% vs. 22.7%, respectively; p=0.8). Similarly, in a larger study of 360 women with LMP tumours, another cohort study found no difference in disease-free survival between patients who underwent radical or fertility-sparing surgery (p=0.651). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;While the surgical technique does not appear to impact patient survival, there have been differences detected in surgical outcomes and complication rates. One study found a statistically significant difference in complication rates, with 12.9% experiencing a complication in the completely staged group versus 1.0% in those incompletely staged (p&amp;lt;0.001). Another study reported a statistically significant difference in the rates of minor postoperative complications, with 6.7% of patients in the laparoscopy group experiencing such an event compared to 42.1% of patients in the laparotomy group (p=0.047). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One group of researchers reported a difference in the cases of tumour rupture or spilling during surgery, with 34.6% ruptures recorded in the laparoscopic group compared to 6.6% in patients undergoing a laparotomy (p&amp;lt;0.0001). Similarly, another research group found 31% of laparoscopic patients experienced intraoperative tumour rupture versus 16% in the laparotomy group. However, this difference did not reach statistical significance. In patients with borderline tumours, the difference in the occurrence of intraoperative tumour rupture was found not to be statistically associated with the surgical approach. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="432" OrdBy="900" Name="Qualifying Statements">
    <Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text">
      <FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of an adnexal mass by colour Doppler technology, using the resistance index (RI), pulsatility index (PI), and peak systolic velocity (PSV) indices, was neither as sensitive nor specific as simple ultrasonography. Furthermore, because of the overlap of vascular parameters between malignant and benign masses, a firm diagnosis based on Doppler evaluation alone can be problematic. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Elevated serum CA-125 levels have been reported in a variety of benign conditions. Because the incidence of ovarian cancer relative to benign gynecologic conditions is lower in premenopausal women, CA-125 values are of limited use in this population. CA-125 levels are elevated in only 50% of early stage ovarian cancers. Caution should be used in interpreting values in such patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The Gynecology Cancer Disease Site Group (DSG) acknowledges that, despite definitions and criteria, it is unrealistic to expect that 100% of ovarian cancers will be identified as suspicious preoperatively. Pathology remains the gold standard. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" />
    </Field>
  </Section>
  <Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline">
    <Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many">
      <FieldValue Value="Getting Better" />
    </Field>
    <Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many">
      <FieldValue Value="Effectiveness" />
    </Field>
  </Section>
  <Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability">
    <Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation">
      <FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dodge J, Covens A, Lacchetti C, Elit L, Le T, Devries-Aboud M, Fung Kee Fung M, Gynecology Cancer Disease Site Group. Management of a suspicious adnexal mass. Toronto (ON): Cancer Care Ontario (CCO); 2011 Jul 7. Various p.&amp;nbsp;(Evidence-based series; no. 4-15).&amp;nbsp; [294 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" />
    </Field>
    <Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text">
      <FieldValue Value="2011 Jul 7 (reaffirmed 2016 Oct 31)" />
    </Field>
    <Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p">
      <FieldValue Value="Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]" />
    </Field>
    <Field FieldID="123" OrdBy="1230" ID="448" Name="Guideline Developer Comment" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Program in Evidence-Based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Program in Evidence-Based Care (PEBC) is supported by the Ontario Ministry of Health and Long-Term Care through Cancer Care Ontario. All work produced by the PEBC is editorially independent from its funding source.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Gynecology Cancer Disease Site Group&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For a current list of past and present members, please see the &lt;a href=&quot;https://www.cancercare.on.ca/cms/One.aspx?portalId=1377&amp;amp;pageId=10245&quot; title=&quot;Cancer Care Ontario Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No conflicts of interest were declared for J Dodge, A Covens, C Lacchetti, L Elit, T Le, M Devries-Aboud, or M Fung Kee Fung.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Cancer Care Ontario Program in Evidence-Based Care (CCO PEBC) reaffirmed the currency of this guideline in October 2016. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline meets NGC's 2013 (revised) inclusion criteria. &lt;/p&gt;&#xD;&#xA;&lt;p&gt;The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Please visit the &lt;a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=100599&quot; title=&quot;CCO Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt; for details on any new evidence that has emerged and implications to the guidelines.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Available from the &lt;a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=100599&quot; title=&quot;Cancer Care Ontario Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Program in evidence-based care handbook. Toronto (ON): Cancer Care Ontario (CCO); 2011. 15 p. Available from the &lt;a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=50876&quot; title=&quot;Cancer Care Ontario Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of a suspicious adnexal mass: document assessment and review. Toronto (ON): Cancer Care Ontario (CCO); 2016 Sep 9. Available from the &lt;a href=&quot;https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=100599&quot; title=&quot;Cancer Care Ontario Web site&quot;&gt;Cancer Care Ontario Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on October 18, 2012. The currency of the guideline was reaffirmed by the developer in October 2016 and the summary was updated by ECRI Institute on November 18, 2016. &lt;/p&gt;&lt;/div&gt;" />
    </Field>
    <Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text">
      <FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the &lt;a href=&quot;http://www.cancercare.on.ca/ontariocancernews/copyright.html&quot; title=&quot;Cancer Care Ontario Web site&quot;&gt;Copyright and Disclaimer Statements&lt;/a&gt; posted at the Program in Evidence-Based Care section of the Cancer Care Ontario Web site.&lt;/p&gt;&lt;/div&gt;" />
    </Field>
  </Section>
  <Section SecID="99999" OrdBy="99999" Name="Disclaimer">
    <Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text">
      <FieldValue Value="&lt;p&gt;The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the &lt;a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;&gt;NGC Inclusion Criteria&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" />
    </Field>
  </Section>
</Version>